Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR) -- Ignore unavailable to you. Want to Upgrade?

To: ajs who wrote (2035)	7/20/1998 8:53:00 PM
From: Machaon	Read Replies (1) \| Respond to of 2553

I think that the market hasn't been happy with the slow Carticel growth and GENZL's high burn rate. The slow growth rate can be attributed, somewhat, to - Lack of enthusiasm by AAOS in 1997. (Attitude changed in 1998) - Lack of insurance coverage in 1997. (122 million covered by Mar 98) - Slowdown in Europe in 1st qtr 1998. (Picking up in 2nd qtr) - Long time gap between patient identification and implant. (now < 100 days) GENZL has trained a bunch of surgeons and is targeting the ~95,000 femur, cartilage injuries per year. Today was really nasty. GENZL is now valued at under $100 million in capitalization. I am really hoping that this Wednesday's earnings report shows that the Carticel business is coming together. I'm betting that things are coming together, after all of the efforts by GENZL, up to this point, and into the future. So, I almost doubled my position today at $5, realizing that it is a fairly risky investment. Good luck, Bob